9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021 and invites investors to participate via webcast and in one-on-one meetings. The presentation will be followed by a virtual Q&A session.
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021 and invites investors to participate via webcast and in one-on-one meetings. The presentation will be followed by a virtual Q&A session.
Jefferies Virtual Healthcare Conference
Date: June 4th, 2021
Time: 12:30 to 12:55 p.m. (ET)
Presenter: John Temperato, CEO of 9 Meters Biopharma
Webcast: https://wsw.com/webcast/jeff174/nmtr/1878903
* a replay will be available following the presentation for 30 days
Please contact your Jefferies representative to schedule virtual one-on-one meetings with the
9 Meters Biopharma management team during the conference.
About Jefferies Virtual Healthcare Conference
The annual June conference will be held virtually with video presentations, keynotes, panels and 1x1/small group meetings via Zoom.
This virtual gathering of over 400 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs will address near- and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.
For further information, please visit: www.Jefferies.com
About 9 Meters Biopharma
9 Meters Biopharma, Inc. (“the Company”) is a rare and unmet needs-focused gastroenterology company. The Company is advancing vurolenatide, a proprietary long-acting GLP-1 agonist, into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for symptom improvement in non-responsive celiac disease.
For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.
Corporate Contacts:
Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com
Media Contact:
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
SOURCE: 9 Meters Biopharma
View source version on accesswire.com:
https://www.accesswire.com/649585/9-Meters-Biopharma-Inc-to-Present-at-the-Jefferies-Virtual-Healthcare-Conference
